Using targeted agents in ovarian cancer, we are discovering not only how these novel
therapies work but are also unveiling the complex 'wiring'of the disease itself, and the …

Ovarian cancer is the second most common gynaecological malignancy and the leading
cause of death from gynaecological cancer. Although in some cases treatment is initially …

There is little doubt that the survival of women with advanced ovarian cancer has improved
over the last two decades. 1 Platinum and paclitaxel are the two key drugs that have now …

Although cure rates remain low and effective screening strategies are elusive, the recent
advances in systemic therapies over the past year highlighted in this review have prolonged …

Both the first-line trials stopped maintenance bevacizumab after 12 and 15 months,
respectively; yet, current data suggest that maintenance therapy should continue at least …

When to start and end antiangiogenesis therapy and the choice of optimal treatment
combinations remain controversial. Further evaluation of personalized novel angiogenesis …

The 3rd International Ovarian Cancer Consensus Conference (OCCC), held 3–5 September
2004, in Baden-Baden, Germany, addressed 12 questions critical to the future directions of …

OBJECTIVE: The unique characteristics of cancer, particularly issues involving the use of
surrogate endpoints in clinical trials, present special challenges in the development of …

Despite an aggressive approach of surgical cytoreduction and adjuvant combination
chemotherapy, ovarian cancer mortality remains a significant problem. We are entering a …

Objective The prognostic value of anti-angiogenesis therapy in ovarian cancer patients is
currently under debate. In this study, we assessed the effects of anti-angiogenesis therapy …